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Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) is a very heterogeneous disease resulting in huge
differences in the treatment response. New individualized therapy strategies including molecular targeting might help
to improve treatment success. In order to identify potential targets, we developed a HNSCC radiochemotherapy cell
culture model of primary HNSCC cells derived from two different patients (HN1957 and HN2092) and applied an
integrative microRNA (miRNA) and mRNA analysis in order to gain information on the biological networks and
processes of the cellular therapy response. We further identified potential target genes of four therapy-responsive
miRNAs detected previously in the circulation of HNSCC patients by pathway enrichment analysis.
Results: The two primary cell cultures differ in global copy number alterations and P53 mutational status, thus
reflecting heterogeneity of HNSCC. However, they also share many copy number alterations and chromosomal
rearrangements as well as deregulated therapy-responsive miRNAs and mRNAs. Accordingly, six common
therapy-responsive pathways (direct P53 effectors, apoptotic execution phase, DNA damage/telomere stress induced
senescence, cholesterol biosynthesis, unfolded protein response, dissolution of fibrin clot) were identified in both cell
cultures based on deregulated mRNAs. However, inflammatory pathways represented an important part of the
treatment response only in HN1957, pointing to differences in the treatment responses of the two primary
cultures. Focused analysis of target genes of four therapy-responsive circulating miRNAs, identified in a previous
study on HNSCC patients, revealed a major impact on the pathways direct P53 effectors, the E2F transcription
factor network and pathways in cancer (mainly represented by the PTEN/AKT signaling pathway).
Conclusions: The integrative analysis combining miRNA expression, mRNA expression and the related cellular
pathways revealed that the majority of radiochemotherapy-responsive pathways in primary HNSCC cells are
related to cell cycle, proliferation, cell death and stress response (including inflammation). Despite the
heterogeneity of HNSCC, the two primary cell cultures exhibited strong similarities in the treatment response. The
findings of our study suggest potential therapeutic targets in the E2F transcription factor network and the PTEN/AKT
signaling pathway.
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Background
Head and neck squamous cell carcinoma (HNSCC) in-
cludes epithelial cancers of the lip, oral cavity, nasal cavity,
paranasal sinuses, salivary glands, larynx and pharynx
(nasopharynx, oropharynx and hypopharynx) [1] and rep-
resents the sixth most common cancer in the world [2]
with an average 5-year survival rate of approximately 65 %
[3]. Some of the tumors are unresectable because of their
complex anatomy [4]. In addition, HNSCC is usually not
detected in the early stages of the disease due to the lack
of clinical symptoms, which aggravates treatment [5]. The
challenges in treating HNSCC tumors are functional pres-
ervation of substantial organs, such as salivary glands, and
minimization of side effects, such as dysphagia. Moreover,
HNSCC tumors show a high degree of heterogeneity and
variation in the therapeutic response requiring individual-
ized treatment strategies [6, 7]. In order to address these
issues, combined and targeted treatment strategies as well
as more effective treatment monitoring is needed to im-
prove therapy outcomes and patients’ quality of life.
MicroRNAs (miRNAs) represent a class of non-coding
RNAs acting as posttranscriptional gene expression regu-
lators by inhibiting translation or destabilizing mRNAs.
They are known to be involved in regulating and coordin-
ating multiple cellular pathways and processes. MiRNAs
show a response to various cellular stressors and are key
players in many diseases such as cancer [8]. Specific
miRNA signatures were discovered for several tumor
types [9]. For HNSCC a considerable number of miR-
NAs were identified as promising molecular biomarkers
for diagnosis and prognosis targeting either oncogenic
or tumor suppressor transcripts [10–12]. However,
there is still uncertainty concerning the functional role
of most of the miRNAs since one miRNA may target
multiple mRNAs while one mRNA can be regulated by
a number of different miRNAs.
Network-based integrative analysis combining molecu-
lar data from multiple levels represents a valuable tool for
a better understanding of complex signaling networks and
related biological processes. Correlation analysis of ex-
pression values of potentially interacting molecules en-
ables reconstruction of interaction networks based on
experimental data. In this study integrative analysis of
miRNA and mRNA profiles based on the identification of
correlating expression patterns revealed potential func-
tional relationships and pathways involved in the cellular
treatment response [13]. The analysis can be strengthened
by integration of data bases on previously validated target
interactions. Another tool for the in silico investigation of
interactions is pathway enrichment analysis, which anno-
tates molecules of interest, e.g. differentially expressed
genes, to cellular pathways based on over-representation
using the information of pathway databases, such as
Reactome [14].
The aim of the current study was to shed light on the
cellular functions of therapy-responsive miRNAs and to
gain additional information on the treatment effects on
cellular processes and pathways in order to enable the
identification of potential therapeutic targets. For this
purpose we used primary HNSCC cells as a cell culture
model for radiochemotherapy [15] and performed inte-
grative analysis of the miRNA and mRNA expression
profiles in order to analyze affected pathways for a better
understanding of the response of HNSCC cells to
radiochemotherapy.
We aimed to validate our in vitro data by focusing on a
therapy-responsive network of patient-derived data from
a previous study [15].
Results
Characterization of the primary HNSCC cell lines
The newly established HNSCC cell lines HN1957 (naso-
pharynx) and HN2092 (oral cavity) were published in a
previous study, where a cell culture model was established
to simulate radiochemotherapy of a HNSCC patient co-
hort in vitro [15]. For the cell culture model primary cell
cultures were selected instead of established cell lines
since the features of primary cells are closer to the condi-
tions in the patient. A further selection criterion for the
primary cell lines was that they were derived from tumor
sites, that were also represented in the HNSCC patient co-
hort [15]. Apart from that, we selected one P53-mutated
(HN1957) and one P53 wild type (HN2092) primary cell
line. A nasopharyngeal carcinoma was included since
standard treatment for these tumors is radiotherapy or ra-
diochemotherapy due to their high sensitivity towards this
treatment [16]. Characteristics of the primary cells lines
are listed in Table 1. In the present study we used the ra-
diochemotherapy cell culture model in order to gain infor-
mation on the molecular radiochemotherapy response. As
it was already shown before, HN1957 demonstrated a
higher decrease in cellular viability following treatment
with ionizing radiation and 5-fluorouracil (5-FU) com-
pared to HN2092 [15]. To further characterize the two cell
lines in this study we conducted array comparative gen-
omic hybridization CGH (array CGH) analysis, spectral
karyotyping (SKY), P53 and EGFR sequencing analysis as
well as EGFR and EpCAM surface expression.
Array CGH demonstrated 30 copy number alterations
involving 18 chromosomes in HN1957 and 46 copy num-
ber alterations involving 19 chromosomes in HN2092
(Additional files 1, 2, 3A and 4A). SKY revealed the
following clonal karyotype for HN1957 resulting from
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(14)t(13;14)(qter→ q11;p11→ qter),+15,i(15)(q10),+16,+17,+
19,+20,+21,+22,i(22)(q10). A representative metaphase is
shown in Additional file 3B.
HN2092 exhibited the following clonal karyotype







Additional file 4B shows a representative metaphase.
The karyotypes reflected many of the copy number
alterations that were detected by array CGH in HN1957
(isochromosomes, gains of chromosomes and chromo-
some arms: 5p, 7p, 8, 9, 11, 13q, 15, 17q, 20) and HN2092
(isochromosomes, gains of chromosomes and chromosome
arms: 5p, 8, 9, 11q, 12q, 13q, 14, 16, 20).
Further, sequencing analysis revealed no mutations of
EGFR in both cell cultures, but two point mutations of
the P53 gene in HN1957 (P72R and Δ331). Both cell cul-
tures strongly overexpressed EGFR and EpCAM com-
pared to OKF6-hTERT keratinocytes as determined by
flow cytometry surface staining (Additional file 5).
MiRNA and mRNA expression following
radiochemotherapy treatment
In order to analyze common features and differences in
the radiochemotherapy response on the miRNA and
mRNA level, expression changes were assessed following
treatment in both primary cell lines. Significantly deregu-
lated miRNAs in the primary cells after radiochemotherapy
treatment were previously reported by Summerer et al.
[15]. A heatmap of the expression profiles of the top 50
deregulated miRNAs revealed distinctive patterns for
the two different tumor cell cultures (Fisher’s exact
test p = 0.001) as well as for untreated and treated
samples (three biological and two technical replicates
each) resulting in significant or close to significant
clustering (Fisher’s exact test HN1957: p = 0.015,
HN2092: p = 0.080) (Fig. 1). In HN1957 57 signifi-
cantly deregulated miRNAs were identified while
HN2092 showed deregulated expression of 79 miR-
NAs with an overlap of 27 miRNAs between the two
cell cultures.
Global mRNA expression was measured for both cul-
tures after radiochemotherapy or sham-treatment and
unsupervised hierarchical clustering of the gene expres-
sion patterns using the 50 mRNAs with the highest
variance resulted in two main clusters separating sam-
ples of the two cell cultures (Fisher’s exact test p = 0).
Further, the cluster analysis revealed significant or
border line significant separation of control samples
and treated samples (Fisher’s Exact test HN1957: p = 0,
HN2092: p = 0.061) (Fig. 2).
For HN1957 612 genes (Additional file 6) and for
HN2092 598 genes (Additional file 7) were significantly
(adjusted p-value < 0.05) deregulated after radiochemo-
therapy treatment with an overlap of 190 genes between
both primary cultures.
Pathway enrichment analysis
For a comprehensive insight in the cellular pathways,
which were affected by the radiochemotherapy treat-
ment, a pathway enrichment analysis was applied based
on the significantly deregulated mRNAs. The analysis
exhibited DNA damage/telomere stress induced senes-
cence, direct P53 effectors, cholesterol biosynthesis, dissol-
ution of fibrin clot, unfolded protein response and
apoptotic execution phase as overlap of significantly
(FDR < 0.05) enriched pathways (Additional files 8 and
9). Differences in the treatment response between the
two primary cultures are reflected by pathways such as
TGF-beta signaling pathway, regulation of nuclear
SMAD2/3 signaling, TNF signaling pathway and IL6-
mediated signaling events, which play a role only in the
treatment response in HN1957, but not in HN2092.
MiRNA-mRNA interactions
We further aimed to identify potential miRNA-mRNA
interactions that are part of the treatment response in
order to gain information on the function of the
treatment-responsive miRNAs. Integrative network ana-
lysis of significantly deregulated miRNAs and differentially
expressed mRNAs including adjustment with validated
miRNA-mRNA interactions derived from the miRTarBase
Table 1 Characteristics of primary HNSCC cell cultures
Case HN1957 HN2092











P53-status mutated wild type
Radiosensitivity
α (+/-SD) 0.094 (+/− 0.022)* 0.614 (+/− 0.019)*
β (+/-SD) 0.038 (+/− 0.004)** 0.021 (+/− 0.003)**
SF2 0.71 0.27
Cell type epithelial epithelial
n.a. Not available, SD Standard deviation, SF2 Surviving fraction at 2 Gy
*ttest of α values results in significant difference between HN1957 and
HN2092 (p < 0.05)
**ttest of β values results in significant difference between HN1957 and
HN2092 (p < 0.05)
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[17, 18] resulted in functional miRNA-mRNA networks
affected by radiochemotherapy treatment in HN1957
(Fig. 3) and HN2092 (Fig. 4). The miRNAs appearing in
the interaction networks of both primary cell lines and
their corresponding target mRNAs are combined in Fig. 5.
For technical validation by quantitative real-time PCR
(qRT-PCR) individual miRNA and mRNA candidates
were selected according to the following criteria:
miRNA-mRNA correlation values ≤ −0.8, tumor-related
genes or deregulated miRNAs in blood plasma of
radiochemotherapy-treated HNSCC patients (Tables 2
and 3). In HN1957 upregulation of miR-181b-5p (p =
0.008) as well as miR-425-5p (with a p-value close to the
significance level, p = 0.052) was confirmed. Moreover, for
Fig. 1 Unsupervised hierarchical cluster analysis of the expression levels of the top 50 differentially expressed miRNAs in untreated and
radiochemotherapy treated HN1957 and HN2092 primary HNSCC cells. Control samples (C) were treated with DMSO and sham-irradiated, treated
samples (T) were treated with 5-FU and irradiated with 2 × 2 Gy. A and B represent technical replicates; 1, 2 and 3 represent biological replicates
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the target genes of miR-181b-5p, ASB13 (p = 0.004) and
SEC24C (p = 0.018), a significant downregulation was
confirmed by qRT-PCR as well as downregulation of
TRAPPC9 (p = 0.046). In HN2092 downregulation of miR-
93-5p (p < 0.001) as well as upregulation of miR-181a-5p
(p = 0.001) was validated. MiR-183-5p was upregulated
(with a p-value close to the significance level, p = 0.071)
while downregulation of its target genes ASNS (p = 0.017)
Fig. 2 Unsupervised hierarchical cluster analysis of the expression levels of the top 50 differentially expressed mRNAs in untreated and
radiochemotherapy treated HN1957 and HN2092 primary HNSCC cells. Control samples (C) were treated with DMSO and sham-irradiated, treated
samples (T) were treated with 5-FU and irradiated with 2 × 2 Gy. A and B represent technical replicates; 1, 2 and 3 represent biological replicates
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and IDH2 (p = 0.045) was confirmed by qRT-PCR. Add-
itionally, downregulation of ACTR1B (p = 0.012) and FASN
(p = 0.007) was verified.
Furthermore, qRT-PCR analyses were performed in order
to validate the network showing common interactions of
HN1957 and HN2092 in response to radiochemotherapy-
treatment (Fig. 5). Upregulation of miR-7-5p and miR-17-
5p was verified for both cell lines as well as downregulation
of their target genes SNCA, AMD1, MKI67, BACE1 and
NAGK in HN1957 or HN2092 (Table 4). Additionally,
downregulation of miR-93-5p in HN2092 and upregulation
of its target gene SLC19A1 were verified (Table 4). Spear-
man correlation coefficients demonstrated a negative cor-
relation (≤ −0.5) for five out of the eight miRNA-mRNA
pairs of the combined network (Table 4).
Characterization of the role of therapy-responsive circu-
lating miRNAs on cellular pathways
As it was already shown by Summerer et al. [15], several
miRNAs significantly deregulated in the presented radio-
chemotherapy cell culture model were also detectable as
circulating deregulated miRNAs in HNSCC patients
after radiochemotherapy. In order to gain information
on the function of these therapy-responsive miRNAs
(miR-21-5p, miR-93-5p, miR-106b-5p and miR-425-5p)
all mRNAs that showed negatively correlating expression
values (c ≤ −0.5) in the primary cell cultures and
additionally representing validated targets in the miRTar-
Base were determined (Additional files 10 and 11). Path-
way enrichment analysis (FDR < 0.05) of these potential
target genes revealed predominantly signaling molecules
that represent direct P53 effectors and play a role in
pathways in cancer, cell cycle and the E2F transcription
factor network (Tables 5 and 6). The key players of these
pathways were E2F1, PTEN, AKT2, JUN, HSP90AA1,
KAT2B in HN1957 and JUN, KAT2B, BIRC5, CCND2,
RBL2 in HN2092.
Discussion
In the present study we applied an integrative approach
for the delineation of the effects of radiochemotherapy
on the molecular processes in a HNSCC cell culture
Fig. 3 MiRNA-mRNA interaction network reflecting the response to radiochemotherapy treatment in HN1957. MiRNA-mRNA pairs were generated
based on the correlation coefficient (c≤−0.5) of their expression levels. MiRNAs are shown in purple, potential target genes are shown in green.
Arrows indicate the direction of regulation. The numbers refer to the correlation value of the respective miRNA and mRNA expression levels
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model. Based on these data, we analyzed the cellular
pathways affected by the treatment. The usefulness of
this approach for the identification of regulatory net-
works has already been demonstrated in previous studies
[19, 20]. For the first time we used this approach on a
cell culture model with primary HNSCC cells mimicking
a common therapy regime for HNSCC [4]. In this way
we aimed for a better understanding of the treatment re-
sponse, with respect to a common and individually vary-
ing molecular response.
The observed overlap of deregulated miRNAs and
mRNAs between HN1957 and HN2092 hints to a
partially common response to radiochemotherapy treat-
ment. At the same time, the separation of the two pri-
mary HNSCC cell cultures in distinct clusters for both,
the top 50 deregulated miRNAs (Fig. 1) and mRNAs
(Fig. 2), suggests individual differences in the response
to the treatment. This is consistent with differences be-
tween HN1957 and HN2092 in the sensitivity towards
radiochemotherapy treatment as shown before [15].
Fig. 4 MiRNA-mRNA interaction network reflecting the response to radiochemotherapy treatment in HN2092. MiRNA-mRNA pairs were generated
based on the correlation coefficient (c≤−0.5) of their expression levels. MiRNAs are shown in purple, potential target genes are shown in green.
Arrows indicate the direction of regulation. The numbers refer to the correlation value of the respective miRNA and mRNA expression levels
Fig. 5 Combined network reflecting common miRNA-mRNA interactions between HN1957 and HN2092 in response to radiochemotherapy
treatment. MiRNA-mRNA pairs were generated based on the correlation coefficient (c ≤−0.5) of their expression levels. MiRNAs are shown
in purple, potential target genes in HN1957 are shown in dark green, potential target genes in HN2092 in light green. Arrows indicate the
direction of regulation. The numbers refer to the correlation values of the respective miRNA and mRNA expression levels
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The short-term effect on cellular viability following ra-
diochemotherapy treatment became apparent only in
HN1957, but not in HN2092 [15]. Variations in the
treatment response may be attributed to inter-tumor
heterogeneity among the various types of HNSCC [6]
with regard to the tumor site and the molecular profile
of the tumors [21]. Accordingly, array CGH detected
alterations in both primary cultures that are typical for
HNSCC, such as gains on 5p, 8q, 11q, 9q and 20pq
as well as losses on 3p and 18q (reviewed in [22])
(Additional files 1, 2, 3A and 4A). In addition, alterations
that were unique to one of the primary cell cultures, such
as chromosomal bands on chromosomes 4 and 14,
which were affected only in HN2092 but not in
HN1957, were observed. Structural rearrangements
involving chromosomes 1, 3, 8 and 13 that were de-
tected in HN1957 or HN2092 are in accordance with
previous karyotyping investigations of HNSCC [23].
In addition, so far unpublished rearrangements on
chromosomes 4, 9, 10, 14 and 15 were discovered in
the two primary cell cultures. Altogether, the cytogenetic
analysis demonstrated that both primary cultures
consisted of a rather homogenous cell population
since most of the chromosomal alterations were shown
to be clonal.
We further analyzed the mutational status of P53 and
EGFR since mutations in P53 are common in head and
neck cancers [24] and EGFR represents a key oncogene
in HNSCC [25]. EGFR did not show any mutations in
both primary cultures, whereas HN1957 showed a P53
Table 2 Validation of deregulated miRNAs and correlating target mRNAs in HN1957 after radiochemotherapy treatment
(analyzed with Agilent microarrays and TaqMan single qRT-PCR assays)
miRNA Array qRT-PCR mRNA Array qRT-PCR
FC (p value) FC (p value) FC (p value) FC (p value)
miR-25-3p 0.88 (0.037) 0.89 (0.152) - - -
miR-30a-3p 1.33 (0.013) 1.17 (0.294) FBLN1 0.68 (<0.001) 0.98 (0.775)
miR-30e-5p 1.23 (0.010) 0.83 (0.002) TRAPPC9 0.59 (<0.001) 0.56 (0.046)
miR-93-5p 0.92 (0.023) 1.03 (0.552) IGF2 1.44 (<0.001) not detected
miR-106b-5p 0.95 (0.042) 1.04 (0.830) – – –
miR-125a-5p 1.17 (0.061) 0.99 (0.879) – – –
miR-125b-5p 0.94 (0.072) 1.05 (0.599) ETS1 1.48 (<0.001) 1.18 (0.509)
IGF2 1.44 (<0.001) not detected
TNFAIP3 1.96 (<0.001) 2.14 (0.120)
miR-181b-5p 1.31 (<0.001) 1.12 (0.008) ASB13 0.69 (<0.001) 0.64 (0.004)
SEC24C 0.69 (<0.001) 0.62 (0.018)
miR-425-5p 1.27 (0.004) 1.28 (0.052) – – –
FC Fold change
Table 3 Validation of deregulated miRNAs and correlating target mRNAs in HN2092 after radiochemotherapy treatment
(analyzed with Agilent microarrays and TaqMan single qRT-PCR assays)
miRNA Array qRT-PCR mRNA Array qRT-PCR
FC (p value) FC (p value) FC (p value) FC (p value)
miR-93-5p 0.96 (0.001) 0.84 (<0.001) CCDC88C 1.44 (<0.001) 1.04 (0.890)
miR-99b-5p 1.13 (<0.001) 1.10 (0.502) ACTR1B 0.62 (<0.001) 0.61 (0.012)
miR-181a-5p 1.38 (<0.001) 1.37 (0.001) – – –
miR-183-5p 1.18 (<0.001) 1.18 (0.071) ASNS 0.52 (<0.001) 0.47 (0.017)
IDH2 0.63 (<0.001) 0.62 (0.045)
HSPA1B 0.52 (0.022) 0.81 (0.167)
miR-186-5p 1.15 (0.083) 1.10 (0.147) FASN 0.66 (<0.001) 0.66 (0.007)
miR-197-3p 1.17 (0.025) 1.02 (0.273) FASN 0.66 (<0.001) 0.66 (0.007)
HSPA1B 0.52 (0.022) 0.81 (0.167)
miR-222-3p 1.10 (0.006) 0.95 (0.057) FASN 0.66 (<0.001) 0.66 (0.007)
miR-320a 1.14 (<0.001) 1.07 (0.425) HES6 0.65 (<0.001) 0.52 (0.004)
FC Fold change
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mutation in the SH3 ligand (P72R) and a nonsense mu-
tation (Δ331) in the tetramerization domain (TD). The
polymorphism at position 72 (P72R) in P53 affects the
interaction between some P53 mutants and P73, a P53
homologue that can transcriptionally activate P53 tar-
get genes [26]. The binding ability of P53 and P73 af-
fects the response to chemotherapy in vitro, which
points to a possible impact of the polymorphism in
codon 72 on the chemosensitivity of tumor cells. The
second P53 mutation (Δ331) leads to a truncated pro-
tein, due to a stop codon in the TD. Most of the muta-
tions in the TD lead to defects in oligomerization of
P53, DNA binding, stimulation of the transcription of
reporter genes and growth inhibition of tumor cells
[27]. It has been shown that deletion of the TD, which
impairs the ability of P53 to tetramerize, does not abol-
ish its ability to bind DNA and to stimulate transcrip-
tion, but significantly decreases the overall affinity of
P53 for DNA, thus destabilizing the P53-DNA com-
plexes [28].
Since EGFR is known to be overexpressed in up to
90 % of HNSCC [29] we determined the EGFR expres-
sion levels of HN1957 and HN2092 in comparison to
normal human keratinocytes (OKF6-hTERT). Both pri-
mary HNSCC cultures demonstrated increased relative
expression of EGFR (Additional file 5), which implies a
potential impact of EGFR signaling suggesting an
EGFR-targeted treatment for an improved therapy
response. Additionally, the epithelial cell adhesion
molecule (EpCAM), which is frequently overexpressed in
HNSCC [30], showed higher expression in HN1957 and
HN2092 cells relative to OKF6-hTERT cells (Additional file
5). EpCAM acts as a marker for metastasis and prolifera-
tion representing another potential target for the thera-
peutic response.
The two primary cell cultures, HN1957 and HN2092,
in part showed the same molecular response to radio-
chemotherapy treatment. The similarities became clear
after pathway enrichment analysis that resulted in six
common pathways affected by combined treatment
with ionizing radiation and 5-FU. Among these, the
pathway direct effectors of P53 is likely to represent ef-
fects of both ionizing radiation and 5-FU treatment. 5-
FU is known to stabilize and activate P53 promoting
/Table 4 Validation of miRNA-mRNA interactions in HN1957
and HN2092 in response to radiochemotherapy treatment
(analyzed with TaqMan single qRT-PCR assays)
miRNA FC mRNA FC Spearman correlation
HN1957 miR-7-5p 1.30 SNCA 0.48 0.5
miR-17-5p 1.21 AMD1 0.87 −1.0
MKI67 0.62 1.0
HN2092 miR-7-5p 1.54 HELLS 1.26 −0.5
miR-17-5p 1.13 BACE1 0.96 −1.0
NAGK 0.81 −0.5
miR-93-5p 0.84 CCDC88C 1.04 0.5
SLC19A1 2.38 −1.0
FC Fold change
Table 5 Pathway enrichment analysis of potential target genes in HN1957 for miRNAs responding to therapy in HNSCC patients
(FDR < 0.05)





Pathways in cancer (K) 327 7 0.0004 1.40E-02 E2F1,PTEN,AKT2,MSH6,HSP90AA1,JUN,VEGFA
Direct p53 effectors (N) 133 5 0.0002 1.40E-02 E2F1,PTEN,SP1,JUN,SMARCA4
Hepatitis B (K) 146 5 0.0004 1.38E-02 E2F1,PTEN,AKT2,JUN,YWHAQ
Nonsense-mediated decay (R) 106 5 0.0001 1.55E-02 RPL30,UPF1,SMG7,RNPS1,RPL18A
RNA transport (K) 164 5 0.0006 1.50E-02 EEF1A1,UPF1,RNPS1,EIF4G2,NUP205
E2F transcription factor network (N) 68 4 0.0002 1.44E-02 E2F1,KAT2B,SP1,RRM2
Estrogen signaling pathway (K) 100 4 0.0009 1.69E-02 AKT2,HSP90AA1,SP1,JUN
Glucocorticoid receptor regulatory
network (N)
77 4 0.0003 1.34E-02 SMARCD1,HSP90AA1,JUN,SMARCA4
HIF-1-alpha transcription factor network (N) 66 4 0.0002 2.03E-02 NPM1,SP1,JUN,VEGFA
Huntington disease (P) 121 4 0.0017 2.79E-02 GAPDH,AKT2,AP2A2,JUN
Processing of capped intron-containing
pre-mRNA (R)
138 4 0.0028 3.33E-02 DDX23,PCBP1,RNPS1,NUP205
Prostate cancer (K) 89 4 0.0006 1.56E-02 E2F1,PTEN,AKT2,HSP90AA1
Regulation of androgen receptor activity (N) 49 4 0.0001 1.70E-02 KAT7,HSP90AA1,KAT2B,JUN
Regulation of telomerase (N) 68 4 0.0002 1.44E-02 E2F1,HSP90AA1,SP1,JUN
(B) BioCarta, (K) KEGG Pathway, (N) NCI - Nature Curated Data, (P) pantherdb, (R) Reactome
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P53-mediated apoptosis [31, 32]. P53 is also activated
by radiation-induced DNA-damage [33] and therefore
represents an important cell cycle checkpoint. Another
pathway affected by the treatment in our study was
apoptotic execution phase including histones and mole-
cules involved in DNA fragmentation and chromatin
condensation. A further pathway, which was involved
in the treatment response of both primary cell cultures,
was DNA damage/telomere stress induced senescence. It
is mainly based on histones that were damaged by the
treatment and might reflect effects of ionizing radiation
on the DNA structure. Molecules acting in the choles-
terol biosynthesis also showed deregulation in both
primary cell cultures, suggesting an involvement of
membranes, probably due to an effect of 5-FU on lipids
[34]. Further, the appearance of dissolution of fibrin clot
as a result of the pathway analysis implies that cellular
migration and inflammation was affected by the
treatment since plasminogen activators and inhibitors
regulate cellular adhesion and migration as well as in-
flammatory response [35]. Unfolded protein response
was another pathway playing a role in the cellular treat-
ment response due to deregulated chaperones, which
are part of the cellular stress response [36]. Apart from
that, we were able to validate deregulation of miR-183-
5p and its target gene ASNS following radiochemother-
apy (Table 3). Activation of ASNS transcription is part
of the unfolded protein response and enhances the cel-
lular resistance to drug treatment. Thus it represents a
potential prognostic factor for the outcome of radio-
chemotherapy [37].
The miRNA-mRNA networks showing interactions that
are part of the treatment response revealed three com-
monly deregulated miRNAs, miR-7-5p, miR-17-5p and
miR-93-5p, in the two primary cell lines. For these miRNAs
interactions with several target genes were validated for
each primary cell line, which proves the significance of the
treatment-responsive miRNA-mRNA interactions.
Genes, which are already known as key players in the
response to 5-FU treatment, also appeared in the
miRNA-mRNA networks of the two primary cell cul-
tures. In particular, 5-FU is an anti-metabolite and in-
hibits thymidilate synthase, which catalyzes the synthesis
of thymidylate and is an essential component of DNA
replication and repair [31]. SLC19A1 and DHFR are part
of the folate metabolism, which is necessary for the reac-
tion catalyzed by thymidilate synthase, and therefore
they might represent predictive markers for the efficacy
of 5-FU treatment [38]. Molecules, such as ASNS or
DHFR, that show a response to treatment are potential
candidates for stratification of patients with regard to
their sensitivity to anti-tumor treatment and might be
targets in a specific group of patients for a combinatorial
treatment approach in order to enhance therapy success
[7]. A systems-based prediction of such combinatorial
treatment approaches has recently been reported for
colon cancer by Klinger et al. [39], which would be also
very promising in the case of HNSCC. Based on the
Table 6 Pathway enrichment analysis of potential target genes in HN2092 for miRNAs responding to therapy in HNSCC patients
(FDR < 0.05)
Pathway Number of Proteins in Pathway Proteins from Gene List P-value FDR Genes
ISG15 antiviral
mechanism(R)
71 4 0 <1.000E-03 NUP153,EIF4G2,NUP205,KPNA2
Viral carcinogenesis(K) 206 4 0.0006 1.94E-02 KAT2B,RBL2,CCND2,JUN
HTLV-I infection(K) 260 4 0.0013 3.58E-02 KAT2B,MAD2L1,CCND2,JUN
Aurora B signaling(N) 40 3 0.0001 7.00E-03 BIRC5,NPM1,PSMA3
Signaling events mediated
by HDAC Class I(N)
56 3 0.0002 1.17E-02 NUP153,KAT2B,YY1
E2F transcription factor
network(N)




72 3 0.0003 1.35E-02 BIRC5,CCND2,NPM1
Mitotic Prophase(R) 99 3 0.0009 2.79E-02 NUP153,SET,NUP205
Nonsense-Mediated
Decay(R)
106 3 0.0010 3.07E-02 SMG7,RPL30,RPL7
Cell cycle(K) 124 3 0.0016 3.55E-02 RBL2,MAD2L1,CCND2
Mitotic G1-G1/S phases(R) 134 3 0.0020 3.66E-02 RBL2,CCND2,PSMA3
Mitotic Metaphase
and Anaphase(R)
173 3 0.0042 4.77E-02 BIRC5,MAD2L1,PSMA3
(B) BioCarta, (K) KEGG Pathway, (N) NCI - Nature Curated Data, (P) pantherdb, (R) Reactome
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current study such a systems analysis of HNSCC cells in
response to additional inhibitors and perturbations be-
comes feasible.
Despite many common features, differences in the
molecular treatment response between the two primary
cultures were observed. The pathway enrichment ana-
lysis of treatment-responsive genes revealed pathways
that were only affected in one of the two primary cell
cultures. The TGF-beta signaling pathway was affected
in HN1957 as well as the regulation of nuclear
SMAD2/3 signaling. The two pathways are closely con-
nected since both SMAD2 and SMAD3 are regulated by
TGF-beta [40]. TGF-beta signaling is involved in cellu-
lar processes such as cell growth, cell differentiation
and apoptosis. Further pathways that distinguished the
response of the two primary cell cultures were TNF sig-
naling pathway and IL6-mediated signaling events.
These pathways are both part of inflammatory pro-
cesses which might point to an immunological response
to treatment in HN1957 cells. The cytokines TGF-beta,
IL6 and TNF-alpha are all well-known biomarkers for
treatment complications and prognosis of radiochemo-
therapy success [41, 42]. Accordingly, the miRNA
analysis revealed many miRNAs regulating immune re-
sponse and inflammatory molecules deregulated in
HN1957, but not in HN2092. For example, miR-18a-5p,
miR-106b-5p, miR-92a-3p and miR-125b-5p are known
to play a role in inflammation or immune system [43]
and showed a treatment response only in HN1957.
Moreover, upregulation of miR-181b-5p following
treatment was validated in HN1957. MiR-181b-5p is an
oncogenic miRNA known to be overexpressed in
HNSCC and represents a previously reported link be-
tween inflammation and cancer [44]. Taking all these
differences between HN1957 and HN2092 concerning
the pathways involved in the molecular treatment re-
sponse into account, some of the discovered pathways
might be important for prognosis of the individual ther-
apy success. As a consequence this novel knowledge
may be used to deduce more individualized treatment
strategies, e.g. targeting inflammatory pathways which
might lead to a better treatment response [39].
The fact that four miRNAs (miR-21-5p, miR-93-5p,
miR-106b-5p, miR-425-5p) that have already been shown
to be therapy-responsive in blood plasma of HNSCC pa-
tients [15] were also deregulated in the cell culture
model, demonstrates the clinical impact of this study
and links the results of the cell culture model to our in
vivo findings. Therefore, we identified all possible target
molecules of these miRNAs by correlation analysis of
miRNA and mRNA expression values, including only
target interactions that are validated in the miRTarBase
[17, 18]. The four miRNAs were previously described to
play a role in cancer and represent potential diagnostic
or prognostic biomarkers. MiR-106b-5p and miR-21-5p
were suggested as biomarkers in laryngeal carcinoma
[45]. Moreover, miR-106b-5p has been shown to pro-
mote cell migration and invasion by targeting PTEN [46]
while miR-21-5p is overexpressed in various cancer types
and was reported as a prognostic biomarker in head and
neck cancer [47]. MiR-425-5p and miR-93-5p are known
as regulators in cell proliferation [48, 49]. MiR-93-5p is
also targeting the PTEN/AKT signaling pathway, thus in-
fluencing drug sensitivity of cancer cells [50]. The path-
way enrichment analysis based on the target genes of
these miRNAs revealed mostly signaling molecules that
represent direct P53 effectors such as PTEN, JUN and
E2F1 as well as cell cycle regulators such as RBL2,
CCND2, RRM2 and E2F1. The E2F transcription factor
network including genes such as E2F1, RRM2, RBL2,
KAT2B represents a crucial target of the four selected
miRNAs in both primary HNSCC cultures, which might
be due to the fact that E2F1 impacts thymidilate syn-
thase expression, which is a major target of 5-FU as
already discussed [51]. Furthermore, several studies re-
port an influence of deregulation of the E2F transcrip-
tion factor network on the chemoradiation sensititvity of
cancer cells [52–54]. Most of the genes, that are in-
volved in many of the significantly enriched pathways,
also play a role in pathways in cancer such as PTEN,
JUN, AKT2, HSP90AA1, the latter of which was already
described to influence radiosensitivity and chemosensi-
tivity [55]. Also PTEN is a well-known radiosensitizer
enhancing cell death through AKT signaling [56]. The
results presented in this study open up the possibility
of new treatment strategies that target the therapy-
responsive signaling pathways either directly or on
the level of the miRNAs regulating the signaling
molecules.
Conclusions
Important progress in strategies for treatment of HNSCC
has been made over the past decades, however, dose escal-
ation studies revealed that classical radiochemotherapy has
reached some sort of dead end [57]. Therefore, a combin-
ation of radiochemotherapy with molecularly targeted
agents might open up new therapeutic possibilities. This re-
quires the identification of prognostic targets that enable
individualized treatment strategies and allow prevention of
excessive therapy.
In the present study we showed that the main path-
ways affected by radiochemotherapy in two different
HNSCC primary cultures are related to cell cycle and
proliferation, cell death and stress response. As a differ-
ence between the two cell cultures we discovered an em-
phasis on inflammation in the treatment response of
HN1957. This suggests the use of inflammatory path-
ways for stratification of HNSCC patients in order to
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identify individuals who might benefit from an additional
therapy targeting inflammatory pathways.
Similar pathways emerged from the analysis of potential
targets of four miRNAs that showed a treatment response
in the plasma of HNSCC patients and the cell culture
model, suggesting potential molecular therapeutic targets
in the E2F transcription factor network and the PTEN/
AKT signaling pathway. This leads to the conclusion that
promising prognostic markers and molecules for a tar-
geted therapy approach in HNSCC patients are most
likely to be found among those signaling molecules which
needs to be further investigated on clinical samples.
Methods
Primary HNSCC cell cultures
The primary HNSCC cell cultures, HN1957 and HN2092,
were previously described by Summerer et al. [15]. Char-
acteristics of the two primary cell cultures are listed in
Table 1. Molecular characterization of the primary cell
cultures included array CGH, SKY, sequence analysis of
TP53 and EGFR and determination of EGFR and EpCAM
protein expression levels on the cell surface.
High-Resolution Oligo Array CGH
For array CGH analysis of the primary cell cultures the
SurePrint G3 human CGH Microarray Kit 4x180k
(Agilent Technologies, Santa Clara, CA, AMADID:
022060) was used. Tumor DNA (250 ng) and sex-
mismatched normal reference DNA (250 ng) (Promega,
Madison, WI) were used for hybridization. Hybridization
and data analysis were performed as described by Hess
et al. [58].
SKY
Metaphase preparation was done with 3 h of colcemid
(Roche) treatment followed by hypotonic treatment with
KCl (75 mM) for 25 min and three fixation steps
(20 min each) with methanol-acetic acid (3 + 1) on ice.
After one week of ageing at room temperature meta-
phase preparations were treated with RNase A (50 μg/
mL in 2 x SSC), digested with pepsin (1 mg/ml) for
2 min at 37 °C and dehydrated in a 70, 80, and 100 %
ethanol series. After fixation with 1 % formaldehyde for
10 min metaphases were placed in denaturing solution
(70 % formamide in 2 x SSC) at 72 °C for 7 min followed
by dehydration. Hybridization steps and image analysis
were previously described by Hieber et al. [59].
Sequencing
Complementary DNA was synthesized from cellular
RNA using the SuperScript III First-Strand Synthesis
System for RT-PCR (Invitrogen, Carlsbad, CA) according
to the manufacturer’s protocol using Oligo-dT primer
and 1.6 μg RNA. Subsequently, PCR was performed
using Q5 High-Fidelity DNA Polymerase (New England
Biolabs, Ipswich, MA) with 1 μl of a 1:10 dilution of the
cDNA using the primer combinations in Additional file
12. The protocol was optimized for a 50 μl reaction vol-
ume using 1 μl forward and 1 μl reverse primer and add-
ing 5 μl of 10× cresol red and 1 μl of DMSO. The PCR
was optimized as follows: denaturation for 10 min at
96 °C followed by 35 cycles of 15 s at 96 °C and 8 min at
68 °C and final extension for 10 min at 68 °C. The size
of the PCR-products was checked on a 1 % agarose gel.
The bands were cut out from the gel and DNA was puri-
fied on spin columns. The following BigDye PCR was
performed using the BigDye Terminator V3.1 Kit
(Applied Biosystems, Waltham, MA) with 6 μl of tem-
plate DNA. PCR was carried out with 4 min of denatur-
ation at 96 °C followed by 45 cycles of 30 s 95 °C, 20 s
50 °C and 4 min 60 °C. PCR products were sequenced
on an ABI 3730 DNA Analyzer (Applied Biosystems,
Waltham, MA).
EGFR and EpCAM expression
Surface expression levels of EGFR and EpCAM were
assessed by flow cytometry using fluorescently labeled
antibodies as described before [60]. Briefly, 1×105 cells
were stained with anti-EGFR-PE (clone EGFR.1) and
anti-EpCAM-APC (clone EBA-1) antibodies or the cor-
responding isotype controls (all from BD Biosciences,
Franklin Lakes, NJ) in PBS supplemented with 2 % FCS
for 20 min at 4 °C. Cells were washed twice and analyzed
on an LSRII flow cytometer (BD Biosciences, Franklin
Lakes, NJ). Relative surface expression levels are depicted
as median fluorescence intensities subtracted by the match-
ing isotype controls (means ± standard deviations of 3
technical replicates are given). Expression of EGFR and
EpCAM was measured for HN1957 and HN2092 as well as
for the immortalized keratinocytes OKF6-hTERT [61].
Treatment of HNSCC cells
The treatment of the primary HNSCC cells was designed
to model radiochemotherapy treatment of a HNSCC pa-
tient cohort used in a previous study by Summerer et al.
[15]. Briefly, cells were irradiated with 2 Gy using a 137Cs
source and treated with 5-FU (solved in DMSO; Sigma-
Aldrich, St. Louis, MO). Controls were treated with the
corresponding volumes of DMSO and sham-irradiated.
24 h after the first irradiation a second fraction of 2 Gy
was applied to the 5-FU-treated cells followed by incuba-
tion for 1 h at 37 °C. Cells were harvested by trypsiniza-
tion and stored at −20 °C until further processing.
RNA extraction and quality assessment
Total RNA was extracted from frozen cell pellets (−20 °C)
of treated and untreated primary HNSCC cells using the
miRNeasy mini kit (Qiagen, Venlo, Netherlands) according
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to the manufacturer’s protocol without DNase digest or
small RNA enrichment. Optical density (OD) 260/280
ratios were measured with a Nanodrop ND-1000
(Thermo Scientific) and ranged from 1.92 to 2.04.
RNA-concentrations were measured with a Qubit 2.0
Fluorometer (Invitrogen, Carlsbad, CA) using the
RNA Broad Range Assay Kit (Invitrogen, Carlsbad,
CA). Additionally, RNA quality was assessed prior to
the Agilent microarray experiments using an Agilent
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).
The obtained RNA integrity numbers (RINs) ranged from
9.3 to 10.0. RNA samples were stored at −80 °C until fur-
ther processing.
MicroRNA profiling
MiRNA profiling of primary HNSCC cell cultures was
previously described by Summerer et al. [15].
Quantification of individual miRNAs by real-time PCR
Reverse transcription was performed on a Cyclone PCR
system (Peqlab, Erlangen, Germany) using the TaqMan
miRNA reverse transcription kit and miRNA-specific
stem-loop primers (Applied Biosystems, Waltham, MA)
according to the manufacturer’s protocol. Quantitative
real-time PCR (qRT-PCR) was performed in duplicates
and included non-template negative controls. A ViiA 7
real-time PCR System (Applied Biosystems, Waltham,
MA) was used according to the manufacturer’s protocol.
The U6 snRNA was used for normalization. Fold
changes were calculated using the 2-ΔΔCt method [62].
P-values were computed using the student’s t-test.
Global gene expression analysis
To identify potential targets of deregulated miRNAs, a gene
expression profiling was performed with G3 Human Gene
Expression 8×60k v2 microarrays (Agilent Technologies,
Santa Clara, CA, AMADID: 039494) covering over 40,000
transcripts. The gene expression analysis was carried out
according to the manufacturer’s protocol. Total RNA was
extracted from untreated and treated cells as described
above. A one-color microarray experiment with 60 ng of
the same RNA samples that were used for the miRNA ana-
lysis was conducted with three biological and two technical
replicates for each data point. A one-color RNA spike-in kit
(Agilent Technologies, Santa Clara, CA) was used to moni-
tor the workflow. In the first step copyDNA (cDNA) was
generated from the RNA templates followed by transcrip-
tion to copyRNA (cRNA) with incorporation of cyanine 3-
CTP. After hybridization of the labeled cRNA on the arrays
(17 h, 65 °C), the microarrays were scanned with a G2505C
Sure Scan Microarray Scanner (Agilent Technologies, Santa
Clara, CA). Data were extracted with the Feature Extraction
10.7 software (Agilent Technologies, Santa Clara, CA). Data
quality assessment, preprocessing, and normalization were
conducted in R using the Bioconductor AgiMicroRNA
package [63]. In order to identify significantly differentially
expressed genes between treated and untreated cells, statis-
tical analyses were accomplished using the Bioconductor
limma package [64]. A cut-off for FDR-adjusted p-values of
0.05 was applied.
Quantitative real-time PCR quantification of individual
mRNAs
For validation of gene expression microarray data, indi-
vidual mRNAs were quantified via qRT-PCR. 500 ng of
RNA was reverse-transcribed using the QuantiTect
Reverse Transcription Kit (Qiagen, Venlo, Netherlands)
according to the manufacturer’s protocol. qRT- PCR was
performed on a ViiA 7 real-time PCR System (Applied
Biosystems, Waltham, MA) using specific TaqMan gene
expression assays (Applied Biosystems, Waltham, MA).
PCR was carried out in 10 μl reactions consisting of 5 μl
TaqMan PCR Master Mix (no AmpErase UNG), 3.5 μl
H2O, 0.5 μl TaqMan assay and 1 μl cDNA. All reactions
were performed in triplicates and included non-template
negative controls. B2M and ACTB were used as en-
dogenous controls. Fold changes were calculated using
the 2-ΔΔCt method [62]. P-values were computed using
the student’s t-test.
Network analysis
MiRNA-mRNA networks were designed based on inte-
grative analysis of the microarray data. A correlation
matrix was calculated using the expression values of all
significantly deregulated miRNAs and mRNAs, result-
ing in a correlation value for each miRNA-mRNA pair.
Based on the assumption of a negative regulation
mechanism Pearson correlation values of −1 ≤ c ≤ −0.5
were considered to indicate associations. This condition
was used to convert the correlation matrix into a binary
matrix to which we associated a false detection rate cal-
culated after a permutation test. Only miRNA-mRNA
pairs that represented validated interactions (with the
annotation “strong evidence” or NGS-validated targets)
in the miRTarBase [18, 17], were considered. The
miRNA-mRNA pairs that showed significant negative
correlation as well as validated functional interaction
(according to miRTarBase) were visualized with the
yED Graph Editor software [65]. All statistical analyses
were performed using the R Project for Statistical
Computing [66].
Pathway analysis of deregulated mRNAs
To analyze the functional context of the significantly
deregulated genes in the radiochemotherapy cell cul-
ture model a pathway enrichment analysis was per-
formed using the Reactome 4.0.1 application [14] in the
Cytoscape 3.0.2 software [67].
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